Clinical Trial Update: Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports safety, tolerability, and preliminary efficacy data for 21 days of dermal MRX-6 in mild to moderate allergic contact dermatit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Contact Dermatitis

Drugs mentioned

• MRX-6

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Allergic Contact Dermatitis | Phase 1, Phase 2 | Status: COMPLETED